Literature DB >> 30992570

Pembrolizumab improves OS across PD-L1 subgroups.

Conor A Bradley1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30992570     DOI： 10.1038/s41571-019-0213-5

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  3 in total

1.  Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.

Authors:  Ziran Zhao; Yibo Gao; Qi Xue; Shugeng Gao; Jie He
Journal:  Target Oncol       Date:  2021-05-13       Impact factor: 4.493

2.  Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB-IIIB resectable lung squamous cell carcinoma.

Authors:  Dijian Shen; Jiangfeng Wang; Jie Wu; Sheng Chen; Jianqiang Li; Jinshi Liu; Qixun Chen; Youhua Jiang
Journal:  J Thorac Dis       Date:  2021-03       Impact factor: 2.895

3.  Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy.

Authors:  Rong Fu; Chuan-Qing Jing; Xiu-Rong Li; Zhao-Feng Tan; Hui-Jie Li
Journal:  Cancer Manag Res       Date:  2021-06-21       Impact factor: 3.989
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.